Immunotherapy for gynaecological malignancies

Expert Opinion on Biological Therapy

Volumn 5, Issue 9, 2005, Pages 1193-1210

  Coukos, George ^a   Conejo Garcia, Jose R ^a   Roden, Richard B S ^b   Wu, T C ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Cervical cancer; Cytokine; HPV; Immunotherapy; Lymphocyte; Ovarian cancer; Tumour infiltrating; Vaccine development

Indexed keywords

BRCA1 PROTEIN; CANCER VACCINE; CYTOCHROME P450 1B1; DENDRITIC CELL VACCINE; DNA VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FOLATE BINDING PROTEIN; HEAT SHOCK PROTEIN 65; LIPOPROTEIN; LIVE VACCINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CA125; MUCIN 1; OREGOVOMAB; PLASMID DNA; PROTEIN E6; PROTEIN E7; PROTEIN P53; RECOMBINANT PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VIRUS VACCINE; ZYC 101;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN EXPRESSION; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; GYNECOLOGIC CANCER; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOGENICITY; NONHUMAN; OVARY CANCER; REVIEW; SIDE EFFECT; T LYMPHOCYTE RECEPTOR GENE; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS CULTURE; VIRUS INFECTION; VIRUS PARTICLE; WART VIRUS;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, HETEROPHILE; ANTIGENS, NEOPLASM; CANCER VACCINES; CLINICAL TRIALS; CYTOKINES; DRUG EVALUATION, PRECLINICAL; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; IMMUNOTHERAPY; LYMPHOCYTES, TUMOR-INFILTRATING; OVARIAN NEOPLASMS; PAPILLOMAVIRIDAE; T-LYMPHOCYTES, REGULATORY; UTERINE CERVICAL NEOPLASMS; VACCINES, ATTENUATED; VIRAL VACCINES;

HUMAN PAPILLOMAVIRUS;

EID: 24144468941     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.5.9.1193     Document Type: Review

References (215)

1. JEMAL A, THOMAS A, MURRAY T, THUN M:Cancer statistics, 2002. CA Cancer J. Clin. (2002) 52:23-47.
2. ROSENBERG SA:The identification of cancer antigens: impact on the development of cancer vaccines. Cancer J. (2000) 6(Suppl. 2):S142-S149.
3. ZENG G:MHC class II-restricted tumor antigens recognized by CD4+ T cells: new strategies for cancer vaccine design. J. Immunother. (2001) 24:195-204.
4. NOVELLINO L, CASTELLI C, PARMIANI G:A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol. Immunother. (2005) 54(3):187-207.
5. SANTIN AD:HER2/neu overexpression: has the Achilles' heel of uterine serous papillary carcinoma been exposed? Gynecol Oncol. (2003) 88:263-265.
6. WAGGONER SE:Cervical cancer. Lancet (2003) 361:2217-2225.
7. ZUR HAUSEN H:Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer (2002) 2:342-350.
8. BREITBURD E KIRNBAUER R, HUBBERT NL et al:Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J. Virol. (1995) 69:3959-3963. This article reports that neutralising IgG mediate protection after rabbit VLP vaccination.
9. SUZICH JA, GHIM SJ, PALMER-HILL FJ et al:Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc. Natl. Acad. Sci. USA (1995) 92:11553-11557. This article reports that neutralising IgG mediate protection after canine VLP vaccination.
10. EMBERS ME, BUDGEON LR, PICKEL M, CHRISTENSEN ND: Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein. J. Virol. (2002) 76:9798-9805.
11. WU TC: Immunology of the human papilloma virus in relation to cancer. Curr. Opin. Immunol. (1994) 6:746-754.
12. HALPERT R, FRUCHTER RG, SEDLIS A, BUTT K, BOYCE JG, SILLMAN FH:Human papillomavirus and lower genital neoplasia in renal transplant patients. Obstet. Gynecol. (1986) 68:251-258.
13. LAGA M, ICENOGLE JP, MARSELLA R et al.:Genital papillomavirus infection and cervical dysplasia-opportunistic complications of HIV infection. Int. J. Cancer (1992) 50:45-48.
14. SCHAFER A, FRIEDMANN W, MIELKE M, SCHWARTLANDER B, KOCH MA:The increased frequency of cervical dysplasia-neoplasia in women infected with the human immunodeficiency virus is related to the degree of immunosuppression. Am. J. Obstet. Gynecol. (1991) 164:593-599.
15. BRANDSMA JL:Animal models for HPV vaccine development. Papillomavirus Rep. (1994) 5:105-111.
16. SELVAKUMAR R, BORENSTEIN LA, LIN YL, AHMED R, WETTSTEIN FO: Immunization with nonstructural proteins E1 and E2 of cottontail rabbit papillomavirus stimulates regression of virus-induced papillomas. J. Virol. (1995) 69:602-605.
17. TAGAMI H:Regression phenomenon of numerous flat warts-an experiment on the nature of tumor immunity in man. Int. J. Dermatol. (1983) 22:570-571.
18. BENTON C, SHAHIDULLAH H, HUNTER JA:Human papillomavirus in the immunosuppressed. Papillomavirus Rep. (1992) 3:23-26.
19. HAGENSEE M, GALLOWAY D: Growing human papillomaviruses and virus-like particles in the laboratory. Papillomavirus Rep. (1993) 4:121-124.
20. ZHOU J, SUN XY, DAVIES H, CRAWFORD L, PARK D, FRAZER IH: Definition of linear antigenic regions of the HPV16 L1 capsid protein using synthetic virion-like particles. Virology (1992) 189:592-599.
21. KIRNBAUER R, BOOY F, CHENG N, LOWY DR, SCHILLER JT:Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl. Acad. Sci. USA (1992) 89:12180-12184. This study demonstrates that L1 has an intrinsic capacity to assemble into empty capsid-like structures with immunogenicity similar to that of infectious virions. It provides a foundation for considering L1 preparations as candidates for a serological test for measuring antibodies to conformational virion epitopes and for a vaccine to prevent papillomavirus infection.
22. SASAGAWA T, PUSHKO P, STEERS G et al.:Synthesis and assembly of virus-like particles of human papillomaviruses Type 6 and Type 16 in fission yeast Schizosaccharomyces pombe. Virology (1995) 206:126-135.
23. NARDELLI-HAEFLIGER D, RODEN RB, BENYACOUB J et al: Human papillomavirus Type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice. Infect. Immun. (1997) 65:3328-3336.
24. CHEN BP, LI YS, ZHAO Y et al:DNA microarray analysis of gene expression in endothelial cells in response to 24-h shear stress. Physiol. Genomics (2001) 7:55-63.
25. KIRNBAUER R:Papillomavirus-like particles for serology and vaccine development. Intervirology (1996) 39:54-61.
26. DONNELLY JJ, MARTINEZ D, JANSEN KU, ELLIS RW, MONTGOMERY DL, LIU MA: Protection against papillomavirus with a polynucleotide vaccine. J. Infect. Dis. (1996) 173:314-320.
27. SOMASUNDARUM K, ZHANG H, ZENG YX et al.:Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p2 IWAF1/CiP1. Nature (1997) 389:187-190.
28. STANLEY MA, MOORE RA, NICHOLLS PKetaL:Intra-epithelial vaccination with COPV L1 DNA by particle-mediated DNA delivery protects against mucosal challenge with infectious COPV in beagle dogs. Vaccine (2001) 19:2783-2792.
29. RUSSELL MW, MOLDOVEANU Z, WHITE PL, SIBERT GJ, MESTECKY J, MICHALEK SM:Salivary, nasal, genital, and systemic antibody responses in monkeys immunized intranasally with a bacterial protein antigen and the cholera toxin b subunit. Infect. Immun. (1996) 64:1272-1283.
30. LOWE RS, BROWN DR, BRYAN JT et al.:Human papillomavirus Type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast. J. Infect. Dis. (1997) 176:1141-1145.
31. BALMELLI C, RODEN R, POTTS A, SCHILLER J, DE GRANDI P, NARDELLI-HAEFLIGER D:Nasal immunization of mice with human papillomavirus Type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions. J. Virol. (1998) 72:8220-8229.
32. MASIAKOS PT, MACLAUGHLIN DT, MAHESWARAN S et al:Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) Type II receptor, bind, and are responsive to MIS. Clin. Cancer Res. (1999) 5:3488-3499.
33. NARDELLI-HAEFLIGER D1 WIRTHNER D, SCHILLER JT et al: Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J. Natl. Cancer Inst. (2003) 95:1128-1137. This study reports the influence of the menstrual cycle and oral contraceptive use on the levels of total and specific antibodies in the cervical secretions of women who had been immunised with HPV-VLPs. Although such vaccination generated relatively high titres of anti-HPV-16 antibodies in the cervix, a decrease in neutralising antibody titres was obseved around ovulation.
34. HARRO CD, PANG YY, RODEN RB et al.:Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J. Natl. Cancer Inst. (2001) 93:284-292.
35. EVANS TG, BONNEZ W, ROSE RC et al.:A Phase I study of a recombinant viruslike particle vaccine against human papillomavirus Type 11 in healthy adult volunteers. J. Infect, Dis. (2001) 183:1485-1493.
36. KOUTSKY LA, AULT KA, WHEELER CM et al:A controlled trial of a human papillomavirus Type 16 vaccine. N. Engl. J. Med. (2002) 347:1645-1651. This paper describes a HPV-L1 VLP trial that produced 100% effective protection from persistent HPV infection. This trial was the first to demonstrate protection against natural transmission of oncogenic HPV after vaccination with L1 VLPs.
37. BROWN DR, BRYAN JT, SCHROEDER JM et al:Neutralization of human papillomavirus Type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titer. J. Infect. Dis. (2001) 184:1183-1186.
38. RODEN RB, GREENSTONE HL, KIRNBAUER R et al.:In vitro generation and type-specific neutralization of a human papillomavirus Type 16 virion pseudotype. J. Virol. (1996) 70:5875-5883.
39. PASTRANA DV, VASS WC, LOWY DR, SCHILLER JT:NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16. Virology (2001) 279:361-369.
40. LOWY DR, FRAZER IH:Chapter 16: Prophylactic human papillomavirus vaccines. J. Natl. Cancer Inst. Monogr. 2003:111-116.
41. RODEN RB, YUTZY WH 4TH, FALLON R, INGLIS S, LOWY DR, SCHILLER JT:Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology (2000) 270:254-257. This study presents evidence of crossreactive neutralising epitopes in L2, providing a rationale for developing L2-specific vaccines.
42. RODEN RB, KIRNBAUER R, JENSON AB, LOWY DR, SCHILLER JT: Interaction of papillomaviruses with the cell surface. J. Virol. (1994) 68:7260-7266.
43. CAMPO MS, GRINDLAY GJ, O'NEIL BW, CHANDRACHUD LM, MCGARVIE GM, JARRETT WF: Prophylactic and therapeutic vaccination against a mucosal papillomavirus. J. Gen. Virol. (1993) 74:945-953.
44. CHRISTENSEN ND, KREIDER JW, KAN NC, DIANGELO SL:The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes. Virology (1991) 181:572-579. This paper and [45] report an early demonstration of the protective efficacy of L2 vaccination in animal models.
45. LIN YL, BORENSTEIN LA, SELVAKUMAR R, AHMED R, WETTSTEIN FO:Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus. Virology (1992) 187:612-619. See [44].
46. KAWANA K, YOSHIKAWA H, TAKETANI Y, YOSHIIKE K, KANDA T: Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6. J. Virol. (1999) 73:6188-6190. This paper reports a common cross-neutralisation epitope for HPV-6 and -16 (located within amino acids 108 - 120 of L2 in HPV-16), suggesting that this epitope may be shared by other genital HPVs. Thus, this paper provides evidence of crossreactive neutralising epitopes in L2.
47. KAWANA Y, KAWANA K, YOSHIKAWA H, TAKETANI Y, YOSHIIKE K, KANDA T:Human papillomavirus Type 16 minor capsid protein L2 N-terminal region containing a common neutralization epitope binds to the cell surface and enters the cytoplasm. J. Virol. (2001) 75:2331-2336.
48. LACEY CJ, THOMPSON HS, MONTEIRO EF et al:Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts. J. Infect. Dis. (1999) 179:612-618.
49. THOMPSON HS, DAVIES ML, WATTS MJ et al.:Enhanced immunogenicity of a recombinant genital warts vaccine adjuvanted with monophosphoryl lipid A. Vaccine (1998) 16:1993-1999.
50. DE JONG A, O'NEILL T, KHAN AY et al.:Enhancement of human papillomavirus (HPV) Type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine (2002) 20:3456-3464.
51. STOLER MH, RHODES CR, WHITBECK A, WOLINSKY SM, CHOW LT, BROKER TR:Human papillomavirus Type 16 and 18 gene expression in cervical neoplasias. Hum. Pathol. (1992) 23:117-128.
52. STOLER MH, WOLINSKY SM, WHITBECKA, BROKERTR, CHOW LT:Differentiation- linked human papillomavirus types 6 and 11 transcription in genital condylomata revealed by in situ hybridization with message-specific RNA probes. Virology (1989) 172:331-340.
53. RUDOLF MP, NIELAND JD, DASILVA DM et al:Induction of HPV16 capsid protein-specific human T cell responses by virus-like particles. Biol. Chem. (1999) 380:335-340.
54. OHLSCHLAGER P, OSEN W, DELL K et al.:Human papillomavirus Type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6mice. J. Virol. (2003) 77:4635-4645.
55. CROOK T, MORGENSTERN JP, CRAWFORD L, BANKS L:Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenorype of cells co-transformed by HPV-16 plus EJ-ras. EMBO J. (1989)8:513-519.
56. KAUFMANN AM, STERN PL, RANKIN EM et al.:Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin. Cancer Res. (2002) 8:3676-3685.
57. ADAMS M, BORYSIEWICZ L, FIANDER A et al.:Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer. Vaccine (2001) 19:2549-2556.
58. BORYSIEWICZ LK, FIANDER A, FIANDER A, NIMAKO M et al.:A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet (1996) 347:1523-1527. This is the first paper to describe a clinical trial of an HPV vaccine utilising a vaccinia virus vector.
59. BALDWIN PJ, VAN DER BURG SH, BOSWELL CM et al.:Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. Clin. Cancer Res. (2003) 9:5205-5213.
60. DAVIDSON EJ, DAVIDSON JA, STERLING JC, BALDWIN PJ, KITCHENER HC, STERN PL: Association between human leukocyte antigen polymorphism and human papillomavirus 16-positive vulval intraepithelial neoplasia in British women. Cancer Res. (2003) 63:400-403.
61. WEISKIRCH LM, PATERSON Y: Listeria monocytogenes: a potent vaccine vector for neoplastic and infectious disease. Immunol. Rev. (1997) 158:159-169.
62. HUSSAIN SF, PATERSON Y:What is needed for effective antitumor immunotherapy? Lessons learned using Listeria monocytogenes as a live vector for HPV-associated tumors. Cancer Immunol. Immunother. (2005) 54(6):577-586.
63. MUDERSPACH L, WILCZYNSKI S, ROMAN L et al:A Phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin. Cancer Res. (2000) 6:3406-3416.
64. STELLER MA, GURSKI KJ, MURAKAMI M et al:Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus Type 16 E7. Clin. Cancer Res. (1998) 4:2103-2109.
65. DAVIDSON EJ, FAULKNER RL, SEHR P et al.:Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7). Vaccine (2004) 22:2722-2729.
66. HALLEZ S, SIMON P, MAUDOUX F et al.:Phase I/II trial of immunogenicity of a human papillomavirus (HPV) Type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia. Cancer Immunol. Immunother. (2004) 53:642-650.
67. CHU NR:Therapeutic vaccination for the treatment of mucosotropic human papillomavirus-associated disease. Expert Opin. Biol. Ther. (2003) 3:477-486.
68. HOPFL R, HEIM K, CHRISTENSEN N et al.:Spontaneous regression of CIN and delayed-type hypersensitivity to HPV-16 oncoprotein E7. Lancet (2000) 356:1985-1986.
69. KLENCKE B, MATIJEVIC M, URBAN RG et al:Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. Clin. Cancer Res. (2002) 8:1028-1037. This study represents the first therapeutic HPV DNA vaccine clinical trial in patients with anal dysplasia. Ten out of twelve patients demonstrated an increased immune response to the peptide epitopes encoded by the DNA vaccine, and three patients experienced partial histological responses. The DNA vaccine was well-tolerated in all of the patients.
70. SHEETS EE, URBAN RG, CRUM CP et al:Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA. Am. J. Obstet. Gynecol. (2003) 188:916-926.
71. GARCIA F, PETRY KU, MUDERSPACH L et al:ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet. Gynecol. (2004) 103:317-326.
72. LANZAVECCHIA A, SALLUSTO F: Regulation of T cell immunity by dendritic cells. Cell (2001) 106:263-266.
73. FIGDOR CG, DE VRIES IJ, LESTERHUIS WJ, MELIEF CJ:Dendritic cell immunotherapy: mapping the way. Nat. Med. (2004) 10:475-480.
74. SANTIN AD, BELLONE S, GOKDEN M, CANNON MJ, PARHAM GP:Vaccination with HPV-18 E7-pulsed dendritic cells in a patient with metastatic cervical cancer. N. Engl. J. Med. (2002) 346:1752-1753.
75. ADAMS M, NAVABI H, JASANI B et al: Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]:poly [C(12)U] (Ampligen®). Vaccine (2003) 21:787-790.
76. DUDLEY ME, WUNDERLICH JR, ROBBINS PF et al.:Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 298:850-854. This influential report represents the first successful use of adoptive cell transfer with TILs following non-myeloablative chemotherapy for the treatment of patients with melanoma.
77. ROSENBERG SA, YANG JC, RESTIFO NP:Cancer immunotherapy: moving beyond current vaccines. Nat. Med. (2004) 10:909-915. A critical evaluation of cancer vaccine approaches available at present, which emphasise alternative strategies that mediate cancer regression in clinical models.
78. SANTIN AD, HERMONAT PL, RAVAGGI A et al:Phenotypic and functional analysis of tumor-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and peripheral blood lymphocytes in patients with advanced ovarian cancer. Gynecol. Obstet. Invest. (2001) 51:254-261.
79. NEGUS RP, STAMP GW, HADLEY J, BALKWILL FR:Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am. J. Pathol. (1997) 150:1723-1734.
80. SCHONDORF T, ENGEL H, KURBACHER CM et al:Immunologic features of tumor-infiltrating lymphocytes and peripheral blood lymphocytes in ovarian cancer patients. J. Soc. Gynecol. Investig. (1998) 5:102-107.
81. KOOI S, ZHANG HZ, PATENIA R, EDWARDS CL, PLATSOUCAS CD, FREEDMAN RS:HLA class I expression on human ovarian carcinoma cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro in low concentrations of recombinant interleukin-2. Cell. Immunol. (1996) 174:116-128.
82. HAYASHI K, YONAMINE K, MASUKO-HONGO K et al.:Clonal expansion of T cells that are specific for autologous ovarian tumor among tumor-infiltrating T cells in humans. Gynecol. Oncol. (1999) 74:86-92.
83. HALAPI E, YAMAMOTO Y, JUHLIN C et al:Restricted T cell receptor V-beta and J-beta usage in T cells from interleukin-2-cultured lymphocytes of ovarian and renal carcinomas. Cancer Immunol. Immunother. (1993) 36:191-197.
84. FISK B, BLEVINS TL, WHARTON JT, IOANNIDES CG:Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J. Exp. Med. (1995) 181:2109-2117.
85. KOOI S, FREEDMAN RS, RODRIGUEZ-VILLANUEVA J, PLATSOUCAS CD:Cytokine production by T-cell lines derived from tumor-infiltrating lymphocytes from patients with ovarian carcinoma: tumor-specific immune responses and inhibition of antigen-independent cytokine production by ovarian tumor cells. Lymphokine Cytokine Res. (1993) 12:429-437.
86. PEOPLES GE, GOEDEGEBUURE PS, SMITH R, LINEHAN DC, YOSHINO I, EBERLEIN TJ:Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc. Natl. Acad. Sci. USA (1995) 92:432-436.
87. PEOPLES GE, ANDERSON BW, FISK B, KUDELKA AP, WHARTON JT, IOANNIDES CG:Ovarian cancer-associated lymphocyte recognition of folate binding protein peptides. Ann. Surg. Oncol. (1998) 5:743-750.
88. DADMARZ RD, ORDOUBADI A, MIXON A et al:Tumor-infiltrating lymphocytes from human ovarian cancer patients recognize autologous tumor in an MHC class II-restricted fashion. Cancer J. Sci. Am. (1996) 2:263.
89. SANTIN AD, BELLONE S, RAVAGGI A, PECORELLI S, CANNON MJ, PARHAM GP:Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells. Obstet. Gynecol. (2000) 96:422-430.
90. PEOPLES GE, SCHOOF DD, ANDREWS JV, GOEDEGEBUURE PS, EBERLEIN TJ:T-cell recognition of ovarian cancer. Surgery (1993) 114:227-234.
91. IOANNIDES CG, FREEDMAN RS, PLATSOUCAS CD, RASHED S, KIM YP: Cytotoxic T cell clones isolated from ovarian tumor-infiltrating lymphocytes recognize multiple antigenic epitopes on autologous tumor cells. J. Immunol. (1991) 146:1700-1707.
92. IOANNIDES CG, PLATSOUCAS CD, RASHED S, WHARTON JT, EDWARDS CL, FREEDMAN RS:Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites. Cancer Res. (1991) 51:4257-4265.
93. FREEDMAN RS, TOMASOVIC B, TEMPLIN S et al:Large-scale expansion in interleukin-2 of tumor-infiltrating lymphocytes from patients with ovarian carcinoma for adoptive immunotherapy. j. Immunol. Methods (1994) 167:145-160.
94. SCHLIENGER K, CHU CS, WOO EY et al:TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. Clin. Cancer Res. (2003) 9:1517-1527.
95. ZHANG L, CONEJO-GARCIA JR, KATSAROS D et al:Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. (2003) 348:203-213.
96. SCHUMACHER K, HAENSCH W, ROEFZAAD C, SCHLAG PM:Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res. (2001) 61:3932-3936.
97. VESALAINEN S, LIPPONEN P, TALJA M, SYRJANEN K:Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur. J. Cancer (1994) 30A:1797-1803.
98. MARROGI AJ, MUNSHI A, MEROGI AJ et al:Study of tumor infiltrating lymphocytes and transforming growth factor-beta as prognostic factors in breast carcinoma. Int. J. Cancer (1997) 74:492-501.
99. NAITO Y, SAITO K, SHIIBA K et al: CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. (1998) 58:3491-3494.
100. NAKANO O, SATO M, NAITO Y et al: Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res. (2001) 61:5132-5136.
101. HALPERN AC, SCHUCHTER LM: Prognostic models in melanoma. Semin. Oncol. (1997) 24:S2-S7.
102. THURNER B, HAENDLE I, RODER C et al:Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. (1999) 190:1669-1678.
103. KUGLER A, STUHLER G, WALDEN P et al:Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat. Med. (2000) 6:332-336.
104. JOCHAM D, RICHTER A, HOFFMANN L et al:Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomised controlled trial. Lancet (2004) 363:594-599.
105. SOSMAN JA, UNGER JM, LIU PY et al: Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J. Clin. Oncol. (2002) 20:2067-2075.
106. ZHOU J, DUDLEY ME, ROSENBERG SA, ROBBINS PF: Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy. J. Immunother. (2005) 28:53-62.
107. ROBBINS PF, DUDLEY ME, WUNDERLICH J et al:Cutting edge: Persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J. Immunol. (2004) 173:7125-7130.
108. ALBERT ML, DARNELL JC, BENDERA, FRANCISCO LM, BHARDWAJ N, DARNELL RB: Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat. Med. (1998) 4:1321-1324.
109. DARNELL RB:The importance of defining the paraneoplastic neurologic disorders. N. Engl. J. Med. (1999) 340:1831-1833.
110. MURRAY JL, PRZEPIORKA D, IOANNIDES CG:Clinical trials of HER-2/neu-specific vaccines. Semin. Oncol. (2000) 27:71-75; discussion 92-100.
111. DISIS ML, SCHIFFMAN K:Cancer vaccines targeting the HER2/neu oncogenic protein. Semin. Oncol. (2001) 28:12-20.
112. BOOKMAN MA, DARCY KM, CLARKE-PEARSON D, BOOTHBY RA, HOROWITZ IR:Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a Phase II trial of the Gynecologic Oncology Group. J. Clin. Oncol. (2003) 21:283-290.
113. HELLSTROM I, GOODMAN G, PULLMAN J, YANG Y, HELLSTROM KE:Overexpression of HER-2 in ovarian carcinomas. Cancer Res. (2001) 61:2420-2423.
114. DISIS ML, SCHIFFMAN K, GUTHRIE K et al:Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein-based vaccine. J. Clin. Oncol. (2004) 22:1916-1925. This report shows that a HER-2/neu ICD protein vaccine was effective in eliciting HER-2/neu-specific T cell immunity in the majority of ovarian cancer patients who completed the vaccine regimen.
115. DISIS ML, GOODELL V, SCHIFFMAN K, KNUTSON KL: Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients. J. Clin. Immunol. (2004) 24:571-578.
116. BABCOCK B, ANDERSON BW, PAPAYANNOPOULOS I et al:Ovarian and breast cytotoxic T lymphocytes can recognize peptides from the amino enhancer of split protein of the Notch complex. Mol. Immunol. (1998) 35:1121-1133.
117. MILES D, PAPAZISIS K:Rationale for the clinical development of STn-KLH (Theratope(R)) and anti-MUC-1 vaccines in breast cancer. Clin. Breast Cancer (2003) 3(Suppl. 4):S134-S138.
118. HOLMBERG LA, OPARIN DV, GOOLEY T et al:Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE STn-KLH cancer vaccine. Bone Marrow Transplant. (2000) 25:1233-1241.
119. GHAZIZADEH M, OGAWA H, SASAKI Y, ARAKI T, AIHARA K: Mucin carbohydrate antigens (T, Tn, and sialyl-Tn) in human ovarian carcinomas: relationship with histopathology and prognosis. Hum. Pathol. (1997) 28:960-966.
120. TAYLOR-PAPADIMITRIOU J, BURCHELL J, MILES DW, DALZIEL M: MUC1 and cancer. Biochim. Biophys. Acta (1999) 1455:301-313.
121. JUNG BLUTH AA, JUNG BLUTH AA, STOCKERT E et al:NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res. (2003) 63:6076-6083.
122. STOCKERT E, JAGER E, CHEN YT et al:A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J. Exp. Med. (1998) 187:1349-1354.
123. CHEN YT, SCANLAN MJ, SAHIN U et al:A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. USA (1997) 94:1914-1918.
124. VANDERKWAAK TJ, ALVAREZ RD: Immune directed therapy for ovarian carcinoma. Curr. Opin. Obstet. Gynecol. (1999) 11:29-34.
125. SHIH IEM, KURMAN RJ:Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am. J. Pathol. (2004) 164:1511-1518.
126. POTHURI B, LEITAO M, BARAKAT R et al:Genetic analysis of ovarian carcinoma histogenesis. Society of Gynecologic Oncologists 32nd Annual Meeting. Nashville, TN, USA (3-7 March 2001).
127. ORSULIC S, LI Y, SOSLOW RA, VITALE-CROSS LA, GUTKIND JS, VARMUS HE:Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell (2002) 1:53-62.
128. FLESKEN-NIKITIN A, CHOI KC, ENG JP, SHMIDT EN, NIKITIN AY: Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. Cancer Res. (2003) 63:3459-3463.
129. REINARTZ S, KOHLER S, SCHLEBUSCH H et al:Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (Phase Ib/II). Clin. Cancer Res. (2004) 10:1580-1587.
130. BEREK JS:Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab. Expert Opin. Biol. Ther. (2004) 4:1159-1165.
131. BEREK JS, TAYLOR PT, GORDON A et al:Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J. Clin. Oncol. (2004) 22:3507-3516.
132. GORDAN JD, VONDERHEIDE RH: Universal tumor antigens as targets for immunotherapy. Cytotherapy (2002) 4:317-327.
133. VONDERHEIDE RH, HAHN WC, SCHULTZE JL, NADLER LM:The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity (1999) 10:673-679.
134. COUNTER CM, HIRTE HW, BACCHETTI S, HARLEY CB:Telomerase activity in human ovarian carcinoma. Proc. Natl. Acad. Sci. USA (1994) 91:2900-2904.
135. SCARDINO A, GROSS DA, ALVES P et al:HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J. Immunol. (2002) 168:5900-5906.
136. LUBY TM, COLE G, BAKER L, KORNHER JS, RAMSTEDT U, HEDLEY ML:Repeated immunization with plasmid DNA formulated in poly(lactide-co-glycolide) microparticles is well tolerated and stimulates durable T cell responses to the tumor-associated antigen cytochrome P450 1B1. Clin. Immunol. (2004) 112:45-53.
137. OTTO K, ANDERSEN MH, EGGERT A et al:Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin. Vaccine (2005) 23:884-889.
138. ANDERSEN MH, THOR SP:Survivin-a universal tumor antigen. Histol. Histopathol. (2002) 17:669-675.
139. HARRIS JR, MARKL J:Keyhole limpet hemocyanin (KLH): a biomedical review. Micron (1999) 30:597-623.
140. RIBAS A, BUTTERFIELD LH, GLASPY JA, ECONOMOU JS:Current developments in cancer vaccines and cellular immunotherapy. J. Clin. Oncol. (2003) 21:2415-2432.
141. TODRYK S, MCLEAN C, ALI S et al: Disabled infectious single-cycle herpes simplex virus as an oncolytic vector for immunotherapy of colorectal cancer. Hum. Gene Ther. (1999) 10:2757-2768.
142. ISHIDA T, CHADA S, STIPANOV M et al:Dendritic cells transduced with wild-type p53 gene elicit potent anti-tumour immune responses. Clin. Exp. Immunol. (1999) 117:244-251.
143. DIAO J, SMYTHE JA, SMYTH C, ROWE PB, ALEXANDER IE: Human PBMC-derived dendritic cells transduced with an adenovirus vector induce cytotoxic T-lymphocyte responses against a vector-encoded antigen in vitro. Gene Ther. (1999) 6:845-853.
144. BELARDELLI F, FERRANTINI M, PARMIANI G, SCHLOM J, GARACI E: International meeting on cancer vaccines: how can we enhance efficacy of therapeutic vaccines? Cancer Res. (2004) 64:6827-6830.
145. INABA K, TURLEY S, YAMAIDE F et al: Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells. J. Exp. Med. (1998) 188:2163-2173.
146. MACKENSON A, HERBST B, CHEN JL et al:Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int. J. Cancer (2000) 86:385-392.
147. THURNER B, RODER C, DIECKMANN D et al:Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J. Immunol. Methods (1999) 223:1-15.
148. JONULEIT H, GIESECKE-TUETTENBERG A, TUTING T et al:A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int. J. Cancer (2001) 93:243-251.
149. MCILROY D, GREGOIRE M: Optimizing dendritic cell-based anticancer immunotherapy: maturation state does have clinical impact. Cancer Immunol. Immunother. (2003) 52:583-591.
150. DHODAPKAR MV, STEINMAN RM, KRASOVSKY J, MUNZ C, BHARDWAJ N:Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J. Exp. Med. (2001) 193:233-238. This article describes how immature DCs can inhibit the effector T cell function in vivo in humans, and urges caution with the use of immature DCs when trying to enhance tumour or microbial immunity.
151. CONEJO-GARCIA JR, BENENCIA F, COURREGES MC et al: Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat. Med. (2004) 10:950-958. This seminal work describes the identification of a new population of myeloid DCs that turn into endothelial-like cells in the tumour microenvironment, thus contributing to tumour vascularisation. This subset, named vascular leukocytes, represents novel therapeutic targets.
152. CONEJO-GARCIA JR, BUCKANOVICH RJ, BENENCIA F et al:Vascular leukocytes contribute to tumor vascularization. Blood (2005) 105:679-681. This paper reports the identification of a high frequency of vascular leukocytes in human ovarian carcinoma specimens.
153. CURIEL TJ, CHENG P, MOTTRAM P et al:Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res. (2004) 64:5535-5538.
154. CURIEL TJ, WEI S, DONG H et al: Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. (2003) 9:562-567.
155. CHOMARAT P, BANCHEREAU J, DAVOUST J, PALUCKA AK:IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat. Immunol. (2000) 1:510-514.
156. GABRILOVICH D, ISHIDA T, OYAMA T et al:Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood (1998) 92:4150-4166. This work depicts the mechanism by which VEGF is responsible for the defective function of DCs in the tumour microenvironment.
157. GABRILOVICH DI, ISHIDA T, NADAF S, OHM JE, CARBONE DP: Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin. Cancer Res. (1999) 5:2963-2970.
158. CHOMARAT P, BANCHEREAU J: Interleukin-4 and interleukin-13: their similarities and discrepancies. Int. Rev. Immunol. (1998) 17:1-52.
159. AHONEN CL, DOXSEE CL, MCGURRAN SM et al:Combined TLR and CD40 triggering
160. GONG J, NIKRUI N, CHEN D et al: Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J. Immunol. (2000) 165:1705-1711.
161. NAIR S, BOCZKOWSKI D, MOELLER B, DEWHIRST M, VIEWEG J, GILBOA E:Synergy between tumor immunotherapy and antiangiogenic therapy. Blood (2003) 102:964-971. This study shows that there is a strong synergy of antiangiogenic therapy combined with tumour immunotherapy of cancer.
162. BERD D, KAIRYS J, DUNTON C et al: Autologous, hapten-modified vaccine as a treatment for human cancers. Semin. Oncol. (1998) 25:646-653.
163. NEMUNAITIS J, STERMAN D, JABLONS D et al:Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J. Natl. Cancer Inst. (2004) 96:326-331.
164. SOIFFER R, HODI FS, HALUSKA F et al:Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J. Clin. Oncol. (2003) 21:3343-3350.
165. ZITVOGEL L, REGNAULT A, LOZIER A et al:Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat. Med. (1998) 4:594-600. This study shows how exosome-based cell-free vaccines represent a promising alternative to DC adoptive therapy for suppressing tumour growth.
166. TAYLOR DD, GERCEL-TAYLOR C: Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects. Br. J. Cancer (2005) 92(2):305-311.
167. ALBERT ML, PEARCE SF, FRANCISCO LM et al:Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J. Exp. Med. (1998) 188:1359-1368.
168. SAUTER B, ALBERT ML, FRANCISCO L, LARSSON M, SOMERSAN S, BHARDWAJ N: Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J. Exp. Med. (2000) 191:423-434.
169. AVIGAN D:Dendritic cell-tumor fusion vaccines for renal cell carcinoma. Clin. Cancer Res. (2004) 10:6347S-6352S.
170. ARROYO PJ, BASH JA, WALLACK MK: Active specific immunotherapy with vaccinia colon oncolysate enhances the immunomodulatory and antitumor effects of interleukin-2 and interferon alpha in a murine hepatic metastasis model. Cancer Immunol. Immunother. (1990) 31:305-311.
171. BASH JA, WALLACK MK:Vaccinia virus oncolysates in the treatment of malignant melanoma. Cancer Treat. Res. (1988) 43:177-190.
172. SINKOVICS JG:Viral oncolysates as human tumor vaccines. Int. Rev. Immunol. (1991) 7:259-287.
173. FREEDMAN RS, IOANNIDES CG, MATHIOUDAKIS G, PLATSOUCAS CD:Novel immunologic strategies in ovarian carcinoma. Am. J. Obstet. Gynecol. (1992) 167:1470-1478.
174. IOANNIDES CG, DEN OTTER W: Concepts in immunotherapy of cancer: introduction. In Vivo (1991) 5:551-552.
175. SCHIRRMACHER V:Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory. Cancer Immunol. Immunother. (2004) 54(6):587-598.
176. MOBUS V, HORN S, STOCK M, SCHIRRMACHER V:Tumor cell vaccination for gynecological tumors. Hybridoma 12:543-547.
177. AUSTIN FC, BOONE CW:Virus augmentation of the antigenicity of tumor cell extracts. Adv. Cancer Res. (1979) 30:301-345.
178. MELCHER A, TODRYK S, HARDWICK N, FORD M, JACOBSON M, VILE RG:Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat. Med. (1998) 4:581-587.
179. SCHIRRMACHER V, AHLERT T, PROBSTLE T et al:Immunization with virus-modified tumor cells. Semin. Oncol. (1998) 25:677-696.
180. FREEDMAN RS, PLATSOUCAS CD: Immunotherapy for peritoneal ovarian carcinoma metastasis using ex vivo expanded tumor infiltrating lymphocytes. Cancer Treat. Res. (1996) 82:115-146.
181. CANEVARI S, STOTER G, ARIENTI F et al:Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J. Natl. Cancer Inst. (1995) 87:1463-1469.
182. LAMERS CH, BOLHUIS RL, WARNAAR SO, STOTER G, GRATAMA JW:Local but no systemic immunomodulation by intraperitoneal treatment of advanced ovarian cancer with autologous T lymphocytes re-targeted by a bi-specific monoclonal antibody. Int. J. Cancer (1997) 73:211-219.
183. YAMAGUCHI T, BAMBA K, KITAYAMA A et al:Long-term intravenous administration of activated autologous lymphocytes for cancer patients does not induce antinuclear antibody and rheumatoid factor. Anticancer Res. (2004) 24:2423-2429.
184. GREENFIELD EA, NGUYEN KA, KUCHROO VK:CD28/B7 costimulation: a review. Crit. Rev. Immunol. (1998) 18:389-418.
185. ALLISON JP, KRUMMEL MF:The Yin and Yang of T cell costimulation. Science (1995) 270:932-933.
186. BECKER JC, BRABLETZ T, CZERNY C, TERMEER C, BROCKER EB:Tumor escape mechanisms from immunosurveillance: induction of unresponsiveness in a specific MHC-restricted CD4+ human T cell clone by the autologous MHC class II+ melanoma. Int. Immunol. (1993) 5:1501-1508.
187. LEVINE BL, BERNSTEIN WB, CONNORS M et al:Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells. J. Immunol. (1997) 159:5921-5930.
188. LEVINE BL, COTTE J, SMALL CC et al: Large-scale production of CD4+ T cells from HIV-1-infected donors after CD3/CD28 costimulation. J. Hematother. (1998) 7:437-448.
189. MAUS MV, THOMAS AK, LEONARD DG et al:Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat. Biotechnol. (2002) 20:143-148.
190. CONEJO-GARCIA JR, BENENCIA F, COURREGES MC et al:Ovarian carcinoma expresses the NKG2D ligand Letal and promotes the survival and expansion of CD28(-) antitumor T cells. Cancer Res. (2004) 64:2175-2182.
191. CURIEL TJ, COUKOS G, ZOU L et al: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. (2004) 10:942-949. This paper conclusively demonstrates for the first time that tumour-associated regulatory T cells impair the function of T effector cells in tumour-bearing patients.
192. WOO EY, CHU CS, GOLETZ TJ et al: Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. (2001) 61:4766-4772.
193. BLUESTONE JA, ABBAS AK: Natural versus adaptive regulatory T cells. Nat. Rev. Immunol. (2003) 3:253-257.
194. SAKAGUCHI S:Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. (2004) 22:531-562.
195. READ S, POWRIE F:CD4(+) regulatory T cells. Curr. Opin. Immunol. (2001) 13:644-649.
196. WOO EY, YEH H, CHU CS et al:Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J. Immunol. (2002) 168:4272-4276.
197. PHAN GQ, YANG JC, SHERRY RM et al:Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA (2003) 100:8372-8377.
198. HODI FS, MIHM MC, SOIFFER RJ et al:Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl. Acad. Sci. USA (2003) 100:4712-4717.
199. FRANKEL AE, FLEMING DR, HALL PD et al:A Phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia. Clin. Cancer Res. (2003) 9:3555-3561.
200. LE BON A, TOUGH DF:Links between innate and adaptive immunity via Type I interferon. Curr. Opin. Immunol. (2002) 14:432-436.
201. TAKAOKA A, HAYAKAWA S, YANAI H et al:Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature (2003) 424:516-523.
202. RAMBALDI A, INTRONA M, COLOTTA F et al:Intraperitoneal administration of interferon beta in ovarian cancer patients. Cancer (1985) 56:294-301.
203. FUJIWARA K, MARKMAN M, STONEBRAKER B et al:Intraperitoneal interferon-alpha in residual ovarian carcinoma: a Phase II gynecologic oncology group study. Gynecol. Oncol. (1999) 75:10-14.
204. BEREK JS, WELANDER C, SCHINK JC, GROSSBERG H, MONTZ FJ, ZIGELBOIM J:A Phase I-II trial of intraperitoneal cisplatin and alpha-interferon in patients with persistent epithelial ovarian cancer. Gynecol. Oncol. (1991) 40:237-243.
205. MARKMAN M, BELINSON J, WEBSTER K et al:Phase II trial of interferon-beta as second-line treatment of ovarian cancer, fallopian tube cancer, or primary carcinoma of the peritoneum. Oncology (2004) 66:343-346.
206. WEISS K:Safety profile of interferon-alpha therapy. Semin. Oncol. (1998) 25:9-13.
207. HURTEAU JA, BLESSING JA, DECESARE SL, CREASMAN WT: Evaluation of recombinant human interleukin-12 in patients with recurrent or refractory ovarian cancer: a gynecologic oncology group study. Gynecol. Oncol. (2001) 82:7-10.
208. LENZI R, ROSENBLUM M, VERSCHRAEGEN C et al:Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Mullerian carcinoma, gastrointestinal primary malignancies, and mesothelioma. Clin. Cancer Res. (2002) 8:3686-3695.
209. PUJADE-LAURAINE E, GUASTALLA JP, COLOMBO N et al:Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. J. Clin. Oncol. (1996) 14:343-350.
210. WINDBICHLER GH, HAUSMANINGER H, STUMMVOLL W et al:Interferon-gamma in the first-line therapy of ovarian cancer: a randomized Phase III trial. Br. J. Cancer (2000) 82:1138-1144.
211. EDWARDS RP, GOODING W, LEMBERSKY BC et al:Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion. J. Clin. Oncol. (1997) 15:3399-3407.
212. OHTA M, MITOMI T, KIMURA M, HABU S, KATSUKI M:Anomalies in transgenic mice carrying the human interleukin-2 gene. Tokai J. Exp. Clin. Med. (1990) 15:307-315.
213. FREEDMAN RS, KUDELKA AP, KAVANAGH JJ et al:Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma. Clin. Cancer Res. (2000) 6:2268-2278.
214. LIU M, ACRES B, BALLOUL JM et al: Gene-based vaccines and immunotherapeutics. Proc. Natl. Acad. Sci. USA (2004) 101(Suppl. 2):l4567-14571.
215. ODAKA M, STERMAN DH, WIEWRODT R et al:Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-beta gene therapy is attributable to induction of systemic immunity. Cancer Res. (2001) 61:6201-6212.